Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation

P. Lees, Q.A. McKellar, R. Foot, G. Gettinby

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Injections of mild irritants intradermally (carrageenan, zymosan and dextran) and intracaveally (carrageenan)in a tissue cage model of inflammation were used in studies of the pharmacodynamics and pharmacokinetics of tolfenamic acid administered intramuscularly in calves. Inhibition of serum thromboxane (TX) B2 and inflammatory exudate prostaglandin (PG) E2 were used as indicators of the magnitude and time course of blockade of cyclo-oxygenase isoforms COX-1 and COX-2, respectively. Single doses of 2, 4 and 8mgkg−1 tolfenamic acid partially inhibited irritant-induced rises in skin temperature (non-dose dependently) and skin oedema (dose-dependently). These doses also markedly inhibited serum TXB2 synthesis and the duration of inhibition was dose-related. A dose of 2mgkg−1 tolfenamic acid also attenuated skin temperature rise over carrageenan-injected tissue cages, and markedly inhibited exudate PGE2 synthesis, even though drug penetration into both exudate and tissue cage transudate was limited. Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.0411), a high estimated Vdarea (1.79-3.20Lkg−1), an estimated ticase 1/2β of 8.01-13.5011 and Clβ of 0.142-0.175Lkg−1h−1. The actions of tolfenamic acid in inhibiting PGE2 synthesis and in attenuating two of the cardinal signs of inflammation (heat and swelling) suggest that a dosage of 2mgkg−1 administered intramuscularly should be effective clinically as an anti-inflammatory agent.
LanguageEnglish
Pages275-288
Number of pages13
JournalVeterinary Journal
Volume155
Issue number3
DOIs
Publication statusPublished - May 1998

Fingerprint

pharmacology
Culture Diffusion Chambers
pharmacokinetics
Exudates and Transudates
Pharmacokinetics
inflammation
calves
Carrageenan
Inflammation
Dinoprostone
acids
carrageenan
prostaglandin synthase
dosage
Skin Temperature
Irritants
cages
skin temperature
synthesis
Thromboxane B2

Keywords

  • tolfenamic acid
  • inflammation
  • calf
  • pharmacokinetics
  • pharmacodynamics

Cite this

Lees, P. ; McKellar, Q.A. ; Foot, R. ; Gettinby, G. / Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. In: Veterinary Journal. 1998 ; Vol. 155, No. 3. pp. 275-288.
@article{acbcd5fe0b7049aa86307e8793cfe996,
title = "Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation",
abstract = "Injections of mild irritants intradermally (carrageenan, zymosan and dextran) and intracaveally (carrageenan)in a tissue cage model of inflammation were used in studies of the pharmacodynamics and pharmacokinetics of tolfenamic acid administered intramuscularly in calves. Inhibition of serum thromboxane (TX) B2 and inflammatory exudate prostaglandin (PG) E2 were used as indicators of the magnitude and time course of blockade of cyclo-oxygenase isoforms COX-1 and COX-2, respectively. Single doses of 2, 4 and 8mgkg−1 tolfenamic acid partially inhibited irritant-induced rises in skin temperature (non-dose dependently) and skin oedema (dose-dependently). These doses also markedly inhibited serum TXB2 synthesis and the duration of inhibition was dose-related. A dose of 2mgkg−1 tolfenamic acid also attenuated skin temperature rise over carrageenan-injected tissue cages, and markedly inhibited exudate PGE2 synthesis, even though drug penetration into both exudate and tissue cage transudate was limited. Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.0411), a high estimated Vdarea (1.79-3.20Lkg−1), an estimated ticase 1/2β of 8.01-13.5011 and Clβ of 0.142-0.175Lkg−1h−1. The actions of tolfenamic acid in inhibiting PGE2 synthesis and in attenuating two of the cardinal signs of inflammation (heat and swelling) suggest that a dosage of 2mgkg−1 administered intramuscularly should be effective clinically as an anti-inflammatory agent.",
keywords = "tolfenamic acid, inflammation, calf, pharmacokinetics, pharmacodynamics",
author = "P. Lees and Q.A. McKellar and R. Foot and G. Gettinby",
year = "1998",
month = "5",
doi = "10.1016/S1090-0233(05)80024-3",
language = "English",
volume = "155",
pages = "275--288",
journal = "Veterinary Journal",
issn = "1090-0233",
number = "3",

}

Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation. / Lees, P.; McKellar, Q.A.; Foot, R.; Gettinby, G.

In: Veterinary Journal, Vol. 155, No. 3, 05.1998, p. 275-288.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacodynamics and pharmacokinetics of tolfenamic acid in ruminating calves: evaluation in models of acute inflammation

AU - Lees, P.

AU - McKellar, Q.A.

AU - Foot, R.

AU - Gettinby, G.

PY - 1998/5

Y1 - 1998/5

N2 - Injections of mild irritants intradermally (carrageenan, zymosan and dextran) and intracaveally (carrageenan)in a tissue cage model of inflammation were used in studies of the pharmacodynamics and pharmacokinetics of tolfenamic acid administered intramuscularly in calves. Inhibition of serum thromboxane (TX) B2 and inflammatory exudate prostaglandin (PG) E2 were used as indicators of the magnitude and time course of blockade of cyclo-oxygenase isoforms COX-1 and COX-2, respectively. Single doses of 2, 4 and 8mgkg−1 tolfenamic acid partially inhibited irritant-induced rises in skin temperature (non-dose dependently) and skin oedema (dose-dependently). These doses also markedly inhibited serum TXB2 synthesis and the duration of inhibition was dose-related. A dose of 2mgkg−1 tolfenamic acid also attenuated skin temperature rise over carrageenan-injected tissue cages, and markedly inhibited exudate PGE2 synthesis, even though drug penetration into both exudate and tissue cage transudate was limited. Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.0411), a high estimated Vdarea (1.79-3.20Lkg−1), an estimated ticase 1/2β of 8.01-13.5011 and Clβ of 0.142-0.175Lkg−1h−1. The actions of tolfenamic acid in inhibiting PGE2 synthesis and in attenuating two of the cardinal signs of inflammation (heat and swelling) suggest that a dosage of 2mgkg−1 administered intramuscularly should be effective clinically as an anti-inflammatory agent.

AB - Injections of mild irritants intradermally (carrageenan, zymosan and dextran) and intracaveally (carrageenan)in a tissue cage model of inflammation were used in studies of the pharmacodynamics and pharmacokinetics of tolfenamic acid administered intramuscularly in calves. Inhibition of serum thromboxane (TX) B2 and inflammatory exudate prostaglandin (PG) E2 were used as indicators of the magnitude and time course of blockade of cyclo-oxygenase isoforms COX-1 and COX-2, respectively. Single doses of 2, 4 and 8mgkg−1 tolfenamic acid partially inhibited irritant-induced rises in skin temperature (non-dose dependently) and skin oedema (dose-dependently). These doses also markedly inhibited serum TXB2 synthesis and the duration of inhibition was dose-related. A dose of 2mgkg−1 tolfenamic acid also attenuated skin temperature rise over carrageenan-injected tissue cages, and markedly inhibited exudate PGE2 synthesis, even though drug penetration into both exudate and tissue cage transudate was limited. Tolfenamic acid pharmacokinetics were characterized by a relatively short tmax (0.94-2.0411), a high estimated Vdarea (1.79-3.20Lkg−1), an estimated ticase 1/2β of 8.01-13.5011 and Clβ of 0.142-0.175Lkg−1h−1. The actions of tolfenamic acid in inhibiting PGE2 synthesis and in attenuating two of the cardinal signs of inflammation (heat and swelling) suggest that a dosage of 2mgkg−1 administered intramuscularly should be effective clinically as an anti-inflammatory agent.

KW - tolfenamic acid

KW - inflammation

KW - calf

KW - pharmacokinetics

KW - pharmacodynamics

UR - http://dx.doi.org/10.1016/S1090-0233(05)80024-3

U2 - 10.1016/S1090-0233(05)80024-3

DO - 10.1016/S1090-0233(05)80024-3

M3 - Article

VL - 155

SP - 275

EP - 288

JO - Veterinary Journal

T2 - Veterinary Journal

JF - Veterinary Journal

SN - 1090-0233

IS - 3

ER -